04 May 2020 – DMC Biotechnologies welcomes Doug Cameron to the team as an Independent Board member. He joins the Board effective immediately to support DMC’s growth as it moves to commercialization.
Doug brings more than 30 years of experience in the biotech industry and has deep knowledge of technology, commercialization, venture capital, and private equity. He earned a Ph.D. in Biochemical Engineering from MIT and has worked for Cargill, Khosla Ventures, and First Green Partners, among others.
Photo of Doug Cameron
Doug Cameron said, “I have been following DMC for some time as they have demonstrated their technology and advanced from development to commercial deployment. I look forward to joining the team and supporting management as they bring their first products to market.”
Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Doug is a luminary in the field of biotechnology and has been influential in the success of multiple companies in the sector. We are excited and honored to have him join the DMC Board. Doug’s appointment to the Board is another important milestone in our growth as an organization.”
About DMC
DMC is a US biobased specialty chemical company which makes products using microbial fermentation. DMC’s metabolic engineering process simplifies biology to make fermentation more predictable, robust, and efficient. By unleashing the power of biology, DMC is on track to address two of the global challenges of our time: sustainably and affordably feeding a growing world population and reducing greenhouse gas emissions through efficient production of (bio)chemicals. For more information, visit: www.dmcbio.com
DMC media contact:
Kathryn Sheridan
Sustainability Consult
[email protected]
